Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
 - EconoTimes)
NEW ORLEANS, Aug. 18, 2017 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against Allergan, Inc. (NYSE:AGN), if they sold call options, purchased put options and/or sold equity forward contracts of the Company between February 25, 2014 and April 21, 2014, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you sold call options, purchased put options and/or sold equity forward contracts of Allergan and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit http://ksfcounsel.com/cases/nyse-agn to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 29, 2017.
About the Lawsuit
Allergan and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The Complaint asserts claims under Sections 14(e), 20A and 20(a) of the Securities Exchange Act of 1934 relating to the attempted acquisition of Allergan by Valeant and its affiliates in 2014 in which certain Defendants traded on material non-public information relating to the proposed acquisition, which caused investors to sell call options and equity forward contracts at artificially deflated prices and purchase put options at artificially inflated prices.
About Kahn Swick & Foti, LLC
KSF, whose partners include the former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
